结肠炎
免疫系统
环氧合酶
肿瘤坏死因子α
炎症性肠病
药理学
炎症
医学
免疫学
内科学
化学
生物化学
疾病
酶
作者
Dae‐Seung Kim,Sunghee Kim,Ji‐Ye Kee,Yohan Han,Jin Bong Park,Jeong‐Geon Mun,Moon-Jung Joo,Yong‐Deok Jeon,Sujin Kim,Sang‐Hyun Park,Sung‐Joo Park,Jae‐Young Um,Seung‐Heon Hong
标识
DOI:10.1142/s0192415x17500562
摘要
Eclipta prostrata (EP) and its compounds are known to have several pharmacological effects including anti-inflammatory effects. In the present study, we demonstrated that EP improves the dextran sulfate sodium (DSS)-induced colitis symptoms such as body weight loss, colon length shortening and disease activity index. In DSS-induced colitis tissue, EP controls the protein expressions of cyclooxygenase-2 (COX-2) and hypoxia inducible factor-1[Formula: see text] (HIF-1[Formula: see text]). In addition, the release of prostaglandin E2and vascular endothelial growth factor-A were significantly reduced by EP administration. EP also inhibited COX-2 and HIF-1[Formula: see text] expressions in the tumor necrosis factor-[Formula: see text] stimulated HT-29 cells. These inhibitory effects of EP occurred by reducing the phosphorylation of I[Formula: see text]B and the translocation of the nuclear factor-[Formula: see text]B (NF-[Formula: see text]B). Additionally, we found through HPLC analysis that wedelolactone, which is an inhibitor of NF-[Formula: see text]B transcription, was contained in water extract of EP. These results indicate that EP can improve colitis symptoms through the modulation of immune function in intestinal epithelial cells and suggests that EP has the potential therapeutic effect to intestinal inflammation.
科研通智能强力驱动
Strongly Powered by AbleSci AI